Metric Finance
LearnFAQ
LearnFAQ

Learn / EPRX

NASDAQ: EPRX

Eupraxia Pharmaceuticals (EPRX) stock, explained like you're 5

Eupraxia Pharmaceuticals trades on the Nasdaq under the ticker EPRX. It is a small cap company in the pharmaceuticals and biotechnology industry, part of the healthcare sector, with a market value of about 492 million dollars.

Ticker
EPRX
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceuticals and Biotechnology
Size
Small cap, about 492 million dollars

Is Eupraxia Pharmaceuticals a small, medium or large cap company?

No. Eupraxia Pharmaceuticals is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 492 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Eupraxia Pharmaceuticals makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves EPRX stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Eupraxia Pharmaceuticals Inc. (EPRX.TO) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • Eupraxia Pharmaceuticals Inc. (EPRX) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • Eupraxia's trial has administered over 3,000 injections with no treatment related serious events to date. (Stock Titan)
  • (EPRX.WT.A) Trading Advice (EPRX.WT.A:CA) (Stock Traders Daily)
  • Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis (kalkine.ca)

Follow EPRX in your daily brief

Each trading day at 5 PM ET we post what happened to Eupraxia Pharmaceuticals and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow EPRX

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Eupraxia Pharmaceuticals stock

What does Eupraxia Pharmaceuticals do?

Eupraxia Pharmaceuticals trades on the Nasdaq under the ticker EPRX. It is a small cap company in the pharmaceuticals and biotechnology industry, part of the healthcare sector, with a market value of about 492 million dollars.

What is the ticker symbol for Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals trades under the ticker EPRX on the Nasdaq.

What is Eupraxia Pharmaceuticals's market cap?

Eupraxia Pharmaceuticals is a small cap stock with a market cap of about 492 million dollars.

How does Eupraxia Pharmaceuticals make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves EPRX stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow EPRX stock every day?

Add EPRX to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow EPRX daily

A free brief on Eupraxia Pharmaceuticals and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • LLY · ELI LILLY & Co
  • JNJ · Johnson & Johnson
  • ABBV · AbbVie
  • MRK · Merck & Co.

Similar stocks

  • LLYELI LILLY & Co
  • JNJJohnson & Johnson
  • ABBVAbbVie
  • MRKMerck & Co.

Compare EPRX: EPRX vs LLY, EPRX vs JNJ, EPRX vs ABBV

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed